This study aimed to evaluate the diagnostic efficacy of calcofluor white (CFW) staining for sporotrichosis using archival formalin-fixed paraffin-embedded (FFPE) specimens, compared with conventional histochemical stains. A total of 75 FFPE specimens collected between 2010 and 2023 from patients with culture- or sequencing-confirmed sporotrichosis cases were enrolled, with 70 specimens from non-fungal infection cases using as controls. Serial tissue sections were stained with CFW, periodic acid-Schiff (PAS), and Gomori methenamine silver (GMS) staining, respectively. The detection rates, diagnostic accuracy metrics, and storage duration effects were assessed. CFW staining yielded a fungal detection rate of 78.6

e21555 Background: Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Sonidegib, a hedgehog pathway inhibitor (HPI), was approved for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy, by the FDA and EMA. However, the efficacy and safety profile of sonidegib in Chinese patients was unknown. Herein, we present the results from a phase IV study of sonidegib conducted among Chinese patients. Methods: The study (NCT06880848) recruited patients (pts) aged ≥18 years who had locally advanced BCC that was not amenable to radiation therapy, curative surgery, or other local therapies. All patients received 200 mg oral sonidegib once daily for up to 1 year. The primary endpoint was the independent review committee (IRC)-assessed objective response rate (ORR) based on the modified response evaluation criteria in solid tumors (mRECIST). Results: Between June 21, 2023, and July 23, 2024, 160 pts were enrolled and treated. Median age was 68 years (range, 25 – 96 years). As of data cutoff (August 26, 2025), median follow-up was 12·7 months. The IRC-assessed ORR was 58.1% (95% CI 50.1-65.9%), which was consistent across all predefined subgroups. Median duration of response (DOR) and progression-free survival (PFS) by IRC were not reached; the 12-month DOR and PFS rates were 70.8% and 67.4%, respectively. Treatment-related adverse events (TRAEs) were reported in all patients, with most graded 1-2. The most common TRAEs were elevated blood creatine kinase (60.6%), alopecia (44.4%), muscle spasms (33.8%), weight decrease (29.4%), anorexia (24.4%), dysgeusia (23.1%), aspartate aminotransferase increased (21.3%), and alanine aminotransferase increased (20.0%). The incidence of grade ≥3 TRAEs was 28.1%, with elevated blood creatine kinase as the most common (15%). Serious adverse events (SAEs) occurred in 39 patients (24.4%), of which 17 (10.6%) were treatment-related SAEs. TRAEs led to treatment discontinuation in 9 (5.6%) pts. No TRAEs led to death. Conclusions: In Chinese patients with locally advanced BCC, sonidegib demonstrated robust efficacy, consistent with previous reports in global study populations. The safety profile of sonidegib was manageable, and no new safety signals were observed. Clinical trial information: NCT06880848 .

BACKGROUND:D-2570, a TYK2 inhibitor, is currently being developed for autoimmune diseases including psoriasis and ulcerative colitis. OBJECTIVE:To evaluate the efficacy and safety of D-2570 in patients with moderate-to-severe plaque psoriasis. METHODS:In the randomized, double-blind, phase 2 study (NCT06278350), patients were randomized 1:1:1:1 to receive D-2570 at 18/27/36 mg, or placebo once daily for 12 weeks. The primary endpoint was the proportion of patients achieving psoriasis area severity index (PASI) 75 at week 12. Secondary endpoints included PASI 75/90/100 and static Physician Global Assessment (sPGA) score of 0/1, safety, and pharmacokinetic/pharmacodynamic characteristics. RESULTS:At week 12, significantly higher response rates for PASI 75 (85.0% to 90.0%, vs 12.5%, P < .001 for all), PASI 90 (70.7% to 77.5% vs 5.0%, P < .001), PASI 100 (39.0% to 50.0% vs 2.5%, P < .005) and sPGA 0/1 (80.5% to 87.5% vs 20.0%, P < .001) were achieved in patients receiving D-2570 at 18/27/36 mg versus placebo. D-2570 was well tolerated, and most treatment-emergent adverse events were mild/moderate. D-2570 exhibited favorable pharmacokinetic properties and effectively suppressed IL-17A levels in patients. LIMITATIONS:Small sample size, relatively short duration of treatment and follow-up. CONCLUSION:D-2570 demonstrated a high efficacy with favorable safety profile in patients with moderate-to-severe plaque psoriasis.

Patients with progressing facial vitiligo who had been treated with upadacitinib, 308 nm excimer light and upadacitinib combined with 308 nm excimer light were selected for retrospective analysis and comparison of their efficacy and safety. Efficacy was evaluated using the Vitiligo Area Severity Index (VASI) and Dermatology Life Quality Index (DLQI) at baseline, after 8 weeks, and after 20 weeks. The progression of skin lesions was monitored through reflectance confocal microscopy (RCM), while adverse reactions were documented. In the combination treatment group, the average VASI at baseline was 0.875 ± 0.4111, which decreased to 0.56 ± 0.32 at week 8 and 0.23 ± 0.218 at week 20 of follow-up (F = 9.918, p = 0.001). RCM analysis indicated that cases achieving VASI100 showed restoration to normalcy regarding loss of integrity within the pigment ring in lesion areas. Although one patient experienced exacerbation of acne, this condition was manageable with topical medication. In contrast, the average VASI score in the 308 nm excimer light group prior to treatment was recorded at 0.908 ± 0.334; by week twenty, it further declined to an average of 0.495 ± 0.4196. The differences observed were statistically significant (F = 28.644, p < 0.001). For patients in the upadacitinib group, the initial average VASI score was noted as being 0.825 ± 0.34; by twenty weeks it averaged approximately 0.53 ± 0.33; however, these differences did not reach statistical significance (F = 2.87, p = 0.14). The efficacy of the combined treatment group was significantly superior compared to both other groups (F = 3.927, p = 0.026). In conclusion, upadacitinib combined with308nm excimer light represents an effective therapeutic option for progressive facial vitiligo and is associated with fewer adverse reactions as well as improved quality of life for patients.

Abstract. Background:. Guselkumab is effective in treating moderate-to-severe plaque psoriasis; however, data from randomized controlled trials in the Chinese population are limited. This study evaluated and verified the efficacy and safety profile of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis. Methods:. This was a randomized, double-blind, placebo-controlled, phase 4 study. Patients with moderate-to-severe plaque psoriasis were randomized 2:1 to the guselkumab group (guselkumab 100 mg by subcutaneous injection at weeks 0 and 4, then every 8 weeks thereafter through week 44) or the placebo-to-guselkumab group (placebo at weeks 0, 4, and 12, then guselkumab at weeks 16, 20, 28, 36, and 44). Coprimary efficacy endpoints were the proportion of patients achieving Psoriasis Area and Severity Index (PASI) 90 response and the proportion of patients achieving Investigator’s Global Assessment (IGA) 0/1 response at week 16. Results:. Among the 419 patients screened for eligibility between August 25, 2021, and July 21, 2022, 327 patients were enrolled. All 327 randomized patients (mean age, 41.5 [standard deviation, 12.7] years; 259 [79.2%] men) were treated and included in the analyses. At week 16, 103/110 patients assigned to the placebo group at baseline started guselkumab treatment. Most patients completed the study (210 in guselkumab group and 101 in placebo-to-guselkumab group). Significantly higher proportions of patients with guselkumab achieved PASI 90 (82.4% vs. 2.0%; P <0.001) and IGA score 0/1 (88.8% vs. 7.1%; P <0.001) compared with placebo at week 16. At week 48, response rates were maintained in the guselkumab group (PASI 90: 79.2%; IGA 0/1: 82.4%) and increased in the placebo-to-guselkumab group (PASI 90: 80.2%; IGA 0/1: 86.3%). During the first 16 weeks, the incidence of adverse events was comparable between groups (41.9% guselkumab vs. 39.1% placebo) and the incidence of serious adverse events was low (0.9% vs. 5.5%), respectively. Conclusion:. Guselkumab was highly effective and displayed a favorable safety profile for the treatment of moderate-to-severe plaque psoriasis in Chinese patients. Clinical trial registration:. ClinicalTrials.gov, NCT04914429.

Background:Atopic dermatitis (AD) is a common inflammatory disease with heterogeneous clinical features. Certain meaningful phenotypes and clinical features may help better classify AD patients for personalized medicine. To our knowledge, no ideal predictors have been found so far. We aim to investigate clinical predictors for the 4-week efficacy of dupilumab treatment in AD patients in the real world. Methods:Two hundred and thirty-three AD patients treated with dupilumab were enrolled between June 2020 and December 2023. Patients' information, characteristics, and medical history were collected. They were evaluated at the baseline and 4 weeks after dupilumab treatment and divided into groups according to the Investigator's Global Assessment (IGA) and peak pruritus numerical rating scale (PP-NRS) score. Statistical analyses were used to evaluate potential predictors. Results:Age increase, late-onset, erythroderma type, and elevation of total serum IgE level were risk factors for poor response after 4-week treatment. Female, atopic personal or family history, and allergic rhinitis were factors for better response. Multivariate logistic regression analysis showed extrinsic AD had a poor reaction than intrinsic AD (OR=4.792,95% CI 1.460-15.732, p=0.010), so did chronic eczema to acute-subacute eczema (OR=2.386,95% CI 1.247-4.566, p=0.009). Trends to decrease the risk were found for allergic rhinitis (OR=0.315,95% CI 0.202-0.967, p=0.001), and atopic family history (OR=0.442,95% CI 0.159-0.622, p=0.041). Conclusion:Extrinsic AD and chronic lichenoid eczema are risk factors for poor response to 4-week dupilumab treatment, which suggests that AD patients with extrinsic and chronic lichenoid eczema may need more patience for long-term treatment or make other options.

ImportanceChina carries a heavy burden of postherpetic neuralgia, with an unmet need for novel drugs with greater efficacy and less prominent neurotoxic effects than existing calcium channel ligands.ObjectiveTo investigate the efficacy and safety of crisugabalin, an oral calcium channel α2δ-1 subunit ligand, for postherpetic neuralgia.Design, Setting, and ParticipantsThis randomized clinical trial, carried out between November 9, 2021, and January 5, 2023, at 48 tertiary care centers across China had 2 parts. Part 1 was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study consisting of a 2-week screening period, a 7-day run-in period, and a 12-week double-blind treatment period. Part 2 was a 14-week open-label extension study. Investigators, statisticians, trial clinicians, and patients were blinded to trial group assignments. Participants included adults with postherpetic neuralgia with an average daily pain score (ADPS) of at least 4 on the 11-point Numeric Pain Rating Scale over the preceding week, with the exclusion of patients with pain not controlled by prior therapy with pregabalin (≥300 mg/d) or gabapentin (≥1200 mg/d).InterventionsPatients were randomized 1:1:1 to receive crisugabalin, 20 mg twice daily (ie, 40 mg/d), and crisugabalin, 40 mg twice daily (ie, 80 mg/d), or placebo for 12 weeks. Eligible patients received crisugabalin, 40 mg, twice daily during extension.Main Outcome and MeasureThe primary efficacy end point was the change from baseline in ADPS at week 12.ResultsThe study enrolled 366 patients (121 patients receiving crisugabalin, 40 mg/d; 121 patients receiving crisugabalin, 80 mg/d; 124 patients receiving placebo; median [IQR] age, 63.0 [56.0-69.0] years; 193 men [52.7%]). At week 12, the least squares mean (SD) change from baseline in ADPS was −2.2 (0.2) for crisugabalin, 40 mg/d, and −2.6 (0.2) for crisugabalin, 80 mg/d, vs −1.1 (0.2) for placebo, with a least squares mean difference of −1.1 (95% CI, −1.6 to −0.7; P < .001) and −1.5 (−95% CI, −2.0 to −1.0; P < .001) vs placebo, respectively. No new safety concerns emerged.Conclusions and RelevanceCrisugabalin, 40 mg/d, or crisugabalin, 80 mg/d, was well tolerated and demonstrated a statistically significant improvement in ADPS over placebo.Trial RegistrationClinicalTrials.gov Identifier: NCT05140863

Key PointsQuestionWhat is the efficacy of crisugabalin, an oral calcium channel alpha 2 delta -1 subunit ligand, for postherpetic neuralgia? FindingsIn this randomized clinical trial of 366 adults, crisugabalin, 40 mg/d, and crisugabalin, 80 mg/d, for 12 weeks yielded a least squares mean difference of -1.1 (95% CI, -1.6 to -0.7) and -1.5 (-95% CI, -2.0 to -1.0) vs placebo in the change from baseline in the average daily pain scores, establishing superiority of crisugabalin over placebo. MeaningCrisugabalin, 40 mg/d, or crisugabalin, 80 mg/d, caused significantly greater pain reduction over placebo, offering a flexible dose selection depending on individual patient response and tolerability. ImportanceChina carries a heavy burden of postherpetic neuralgia, with an unmet need for novel drugs with greater efficacy and less prominent neurotoxic effects than existing calcium channel ligands. ObjectiveTo investigate the efficacy and safety of crisugabalin, an oral calcium channel alpha 2 delta -1 subunit ligand, for postherpetic neuralgia. Design, Setting, and ParticipantsThis randomized clinical trial, carried out between November 9, 2021, and January 5, 2023, at 48 tertiary care centers across China had 2 parts. Part 1 was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study consisting of a 2-week screening period, a 7-day run-in period, and a 12-week double-blind treatment period. Part 2 was a 14-week open-label extension study. Investigators, statisticians, trial clinicians, and patients were blinded to trial group assignments. Participants included adults with postherpetic neuralgia with an average daily pain score (ADPS) of at least 4 on the 11-point Numeric Pain Rating Scale over the preceding week, with the exclusion of patients with pain not controlled by prior therapy with pregabalin (>= 300 mg/d) or gabapentin (>= 1200 mg/d). InterventionsPatients were randomized 1:1:1 to receive crisugabalin, 20 mg twice daily (ie, 40 mg/d), and crisugabalin, 40 mg twice daily (ie, 80 mg/d), or placebo for 12 weeks. Eligible patients received crisugabalin, 40 mg, twice daily during extension. Main Outcome and MeasureThe primary efficacy end point was the change from baseline in ADPS at week 12. ResultsThe study enrolled 366 patients (121 patients receiving crisugabalin, 40 mg/d; 121 patients receiving crisugabalin, 80 mg/d; 124 patients receiving placebo; median [IQR] age, 63.0 [56.0-69.0] years; 193 men [52.7%]). At week 12, the least squares mean (SD) change from baseline in ADPS was -2.2 (0.2) for crisugabalin, 40 mg/d, and -2.6 (0.2) for crisugabalin, 80 mg/d, vs -1.1 (0.2) for placebo, with a least squares mean difference of -1.1 (95% CI, -1.6 to -0.7; P<.001) and -1.5 (-95% CI, -2.0 to -1.0; P<.001) vs placebo, respectively. No new safety concerns emerged. Conclusions and RelevanceCrisugabalin, 40 mg/d, or crisugabalin, 80 mg/d, was well tolerated and demonstrated a statistically significant improvement in ADPS over placebo. Trial RegistrationClinicalTrials.gov Identifier: NCT05140863 This randomized clinical trial evaluated crisugabalin, 40 mg/d, or crisugabalin, 80 mg/d, compared to placebo in terms of patient outcomes and tolerability.

Objective To identify pathogenic genes in 3 cases of piebaldism,and to explore the genotype-phenotype relationships in piebaldism.Methods Clinical data were collected from 3 patients with piebaldism and their parents at the Department of Dermatology,Henan Provincial People's Hospital from January 2019 to December 2021.Peripheral blood samples were obtained from them and 100 unrelated healthy controls,and DNA was extracted.Whole-exome sequencing technology was used to screen genetic variation sites,and then Sanger sequencing was performed for verification.The deleteriousness of genetic variants was evaluated by using pathogenicity analysis software tools.Results Case 1:a 23-year-old male patient presented with white patches on the forehead,chest,and abdomen for 23 years,and his parents had no similar symptoms;case 2:a 1-year-and 5-month-old male infant presented with white patches on the forehead and abdomen for 1 year,and his parents had no similar symptoms;case 3:a 6-year-old male child presented with white patches on the forehead and limbs for 6 years,and his parents had no similar clinical manifestations.Genetic testing showed that a missense mutation c.2033T＞C(p.L678P)in exon 14 of the KIT gene,a splice site mutation c.2485-1G＞C in exon 18 of the KIT gene,and a heterozygous missense mutation c.2346C＞G(p.F782L)in exon 16 of the KIT gene were identified in the case 1,2,3 respectively,but no above mutations were identified in the patients'parents or 100 unrelated healthy controls.The 3 genetic variants were all novel pathogenic mutations,and all were deleterious mutations.Conclusions Three novel pathogenic mutations in the KIT gene were identified in the 3 cases of piebaldism,namely c.2033T＞C(p.L678P),c.2485-1G＞C,and c.2346C＞G(p.F782L).It was further verified that the severity of piebaldism was closely related to the type and location of KIT gene mutations.

BACKGROUND:Xeligekimab (GR1501) is a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A and has shown potential efficacy in treating moderate-to-severe psoriasis in preliminary trials. OBJECTIVES:To evaluate the efficacy and safety of xeligekimab in Chinese patients with moderate-to-severe psoriasis. METHODS:A total of 420 Chinese patients were randomized to 200 mg xeligekimab every 2 weeks (n = 281) or placebo (n = 139) for the first 12 weeks, followed by an extension of the treatment schedule to xeligekimab every 4 weeks for a further 40 weeks. Efficacy was assessed by evaluating achievement of Physician Global Assessment (PGA) 0/1 and 75%, 90% and 100% improvement in Psoriasis Area and Severity Index (PASI 75, PASI 90 and PASI 100, respectively). The safety profile was also evaluated. RESULTS:At week 12, PASI 75, PASI 90 and PASI 100 were achieved in 90.7%, 74.4% and 30.2% of patients in the xeligekimab group vs. 8.6%, 1.4% and 0% of patients in the placebo group, respectively. PGA 0/1 was achieved in 74.4% patients in the xeligekimab group and 3.6% of patients in the placebo group. PASI 75 and PGA 0/1 were maintained until week 52. No unexpected adverse events were recorded. CONCLUSIONS:Xeligekimab showed high efficacy and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.

BackgroundCombination therapy is required for the treatment of moderate acne vulgaris. However, patient compliance in applying multiple topical formulations is poor.ObjectiveTo assess the efficacy and safety of a fixed-dose combination gel with adapalene 0.1% and clindamycin 1% (adapalene-clindamycin) relative to adapalene 0.1% monotherapy and clindamycin 1% monotherapy in patients with moderate facial acne vulgaris.MethodsThis was a randomized, controlled, assessor-blind, phase III study conducted in patients with moderate facial acne vulgaris.ResultsA total of 1617 patients were enrolled. At week 12, patients in the adapalene-clindamycin gel treatment group showed a significant reduction in the percentage change from baseline in total lesion count (- 66.85%), compared with adapalene alone (- 50.82%) or clindamycin gel alone (- 57.61%). The difference in the least square means of the adapalene-clindamycin gel group and adapalene group, or clindamycin gel group was - 16.08% (95% CI - 19.95% to - 12.21%) and - 9.38% (95% CI - 13.25% to - 5.51%;), respectively. At week 12, 19.28% of participants who received adapalene-clindamycin gel achieved at least 2-grade improvement in IGA, versus 7.74% with adapalene gel (OR 3.05, 95% CI 1.93, 4.80) and 14.77% with clindamycin gel (OR 1.42, 95% CI 0.97, 2.07). The study also achieved all its secondary endpoints. Adverse event rates were mostly mild to moderate and comparable across the three treatment groups.ConclusionAdapalene 0.1%-clindamycin 1% combination gel is well tolerated and demonstrated superior efficacy over 0.1% adapalene gel monotherapy and 1% clindamycin gel monotherapy for the treatment of moderate acne vulgaris.Trial RegistrationClinicalTrials.gov identifier NCT03615768.

Objective To investigate changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis treated with biologics during the coronavirus disease 2019(COVID-19)pandemic.Methods Through printed or electronic questionnaires during February 10th-20th,2023,data were collected from patients with moderate to severe plaque psoriasis treated with biologics in Henan Provincial People's Hospital from June 2019 to January 2023,and changes in the disease condition during the COVID-19 pandemic were investigated.The t test or chi-square test was used for comparisons between groups,univariate analysis and multivariate logistic regression analysis were conducted to investigate the factors contributing to the exacerbation of psoriasis,and stratified analysis was employed to evaluate the disease progression among the patients receiving different biologic therapies following treatment delays.Results A total of 177 patients with moderate to severe plaque psoriasis were collected,including 115 males and 62 females;they were aged 6-83(38.69±14.18)years,with disease duration of 1-50(13.48±9.70)years.Among the patients,74(41.81％)experienced psoriasis exacerbation,154(87.01％)developed COVID-19,and 90(50.85％)experienced delays in psoriasis treatment due to the pandemic.The results of univariate analysis indicated significant associations of psoriasis exacerbation with treatment delays,irregular treatment before the pandemic,and incomplete clearance of skin lesions(P＜0.001 or 0.05),while no correlations were observed between psoriasis exacerbation and COVID-19 or gender(both P＞0.05).Multivariate logistic regression analysis demonstrated that psoriasis exacerbation was associated with treatment delays due to COVID-19(OR=3.34,95％CI:1.35-8.22,P=0.009)and incomplete clearance of skin lesions(OR=3.10,95％CI:1.28-7.50,P=0.012),but not associated with irregular treatment before the pandemic(P=0.130).Among the patients treated with adalimumab,secukinumab,ustekinumab,and ixekizumab,those experiencing treatment delays exhibited higher rates of psoriasis exacerbation than those without treatment delays(all P＜0.05).Conclusion Patients with moderate to severe plaque psoriasis undergoing biologic therapy are prone to disease exacerbation when treatment is delayed due to COVID-19,especially those with incomplete lesion clearance.

Combination therapy is required for the treatment of moderate acne vulgaris. However, patient compliance in applying multiple topical formulations is poor. To assess the efficacy and safety of a fixed-dose combination gel with adapalene 0.1

A 1-year and 9-month-old male proband presented with clustered rice grain-sized flat smooth red papules on the face,trunk and limbs for 1.5 years,without fever,joint swelling,or pain.The proband's sister aged 7 years ever experienced swelling and pain in the finger joints of both hands at the age of 2 years,and had intermittent fever and papules all over the body at the same time,and the papules gradually regressed with the subsidence of fever.The proband's mother aged 27 years suffered from swelling and pain in the finger joints of both hands when she was young,gradually leading to finger deformities,and experienced intermittent knee swelling and pain at the age of 12 years without obvious skin lesions on the body.No abnormality was found in ophthalmological and systemic physical examinations of the 3 patients.Whole-exome sequencing showed that the proband,his sister and mother all had a heterozygous missense mutation c.1001G＞A(p.R334Q)in exon 4 of the NOD2 gene.A diagnosis of Blau syndrome was made.The proband was treated with topical moisturizing cream all over the body;during the 52-week follow-up,no joint swelling and pain or eye symptoms were found in the proband,while erythema and depressed scars were observed on the face,trunk and limbs.The proband's sister and mother were treated with subcutaneous injections of adalimumab at initial doses of 40 mg and 80 mg respectively,followed 1 week later by injections at 20 mg and 40 mg respectively,and then treated with injections at 20 mg and 40 mg respectively every 2 weeks;after 12-week treatment,the joint swelling and pain were markedly relieved in the proband's sister and mother,and most skin lesions subsided in the proband's sister;at week 52 during the follow-up,there was no joint swelling,pain or skin lesions in the proband's sister,and there was no swelling or pain in the knee joints of the proband's mother,while no improvement was observed in her finger deformities.During the treatment,no eye symptoms or adverse reactions were observed neither in the proband's sister nor in his mother.

Background: Alopecia areata (AA) is a CD81 T cellemediated autoimmune disease characterized by nonscarring hair loss. Ivarmacitinib, which is a selective oral Janus kinase 1 inhibitor, may interrupt certain cytokine signaling implicated in the pathogenesis of AA.Objective: To evaluate the efficacy and safety of ivarmacitinib in adult patients with AA who have $25% scalp hair loss. Methods: Eligible patients were randomized 1:1:1:1 to receive ivarmacitinib 2, 4, or 8 mg once daily or placebo for 24 weeks. The primary end point was the percentage change from baseline in the Severity of Alopecia Tool score at week 24.Results: A total of 94 patients were randomized. At week 24, the least squares mean difference in the percentage change from baseline in the Severity of Alopecia Tool score for ivarmacitinib 2, 4, and 8 mg and placebo groups were -30.51% (90% CI, -45.25, -15.76), -56.11% (90% CI, -70.28, -41.95), -51.01% (90% CI, -65.20, -36.82), and -19.87% (90% CI, -33.99, -5.75), respectively. Two serious adverse eventsdfollicular lymphoma and COVID-19 pneumoniadwere reported. Limitations: A small sample size limits the generalizability of the results.Conclusion: Treatment with ivarmacitinib 4 and 8 mg doses in patients with moderate and severe AA for 24 weeks was efficacious and generally tolerated.

目的 确定Blau综合征(Blau syndrome,BS)2例患儿的致病基因,探讨Blau综合征基因型、表型及两者间关系.方法 收集2例Blau综合征患儿及其父母临床资料,采集他们和100例无亲缘关系健康对照者的外周血标本,提取DNA.应用全外显子测序技术筛选患儿基因变异位点,Sanger测序验证.结果 2例患儿分别在NOD2基因第4号外显子存在c.1001G＞A(p.R334Q)和c.1000C＞T(p.R334W)变异,而其父母及100例健康对照者均未发现对应变异.结论 本研究在2例Blau综合征患儿中检测到2个致病变异位点NOD2基因c.1001G＞A(p.R334Q)和c.1000C＞T(p.R334W),同时丰富了 BS的基因型、表型及两者间关系的研究.

BACKGROUND Shikonin, a major component of Lithospermum erythrorhizon, exerts anti-inflammatory and antibacterial effects and expedites wound healing. This study aims to evaluate the anti-inflammatory and antioxidant activities of shikonin in a Sprague-Dawley rat model and cell models using fibroblast and endothelial cells. METHODS The impact of shikonin on the activity of endothelial cells and fibroblasts was examined by cell counting kit 8 and wound-healing assays. A diabetic rat model was constructed, followed by wound creation for treatment with shikonin. Hematoxylin-eosin staining was used to assess pathological changes, and Masson's trichrome method to detect collagen deposition. Immunohistochemistry using antibodies against proliferating cell nuclear antigen and CD31 was conducted to detect proliferation and vascular density. Enzyme-linked immunosorbent assay and immunohistochemistry were carried out to assess pro-inflammatory and anti-inflammatory factor concentrations. Western blot and immunofluorescence were implemented to analyze oxidative stress-related protein expression. RESULTS Shikonin induced the activity of both fibroblasts and endothelial cells. Shikonin treatment contributed to facilitated wound healing and higher healing rates in rats. It also resulted in faster lesion debulking in tissues, reduced inflammatory infiltration, increased collagen deposition, and enhanced angiogenesis. Detection of markers at the wounds showed that shikonin accelerated cell proliferation, enhanced tissue remodeling, and inhibited oxidative stress. CONCLUSION Shikonin stimulates the proliferation and migration of fibroblasts and endothelial cells to promote angiogenesis and tissue remodeling, resulting in faster wound healing.

Dermatitis®Vol. 34, No. 1 Pearls & zebrasDystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With DupilumabLing Yu, Jianbo Wang, Lu Bian, Zhenlu Li, Ming Li, Jianguo Li, and Shoumin ZhangLing YuFrom the ∗Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou†Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, BeijingL.Y. and J.W. contributed equally to this article.Search for more papers by this author, Jianbo WangAddress reprint requests to Jianbo Wang, MS, Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, No. 7 Weiwu Rd, Jinshui District, Zhengzhou, 450000, China. E-mail Address: wangjianbo1020@163.comFrom the ∗Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, ZhengzhouL.Y. and J.W. contributed equally to this article.Search for more papers by this author, Lu BianFrom the ∗Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, ZhengzhouSearch for more papers by this author, Zhenlu LiFrom the ∗Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, ZhengzhouSearch for more papers by this author, Ming Li‡Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.Search for more papers by this author, Jianguo LiFrom the ∗Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, ZhengzhouSearch for more papers by this author, and Shoumin ZhangAddress reprint requests to Shoumin Zhang, MS, Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, No. 7 Weiwu Rd, Jinshui District, Zhengzhou, 450000, China. E-mail Address: zhangshoumin1212@126.comFrom the ∗Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, ZhengzhouSearch for more papers by this authorPublished Online:11 Jan 2023https://doi.org/10.1089/DERM.0000000000000954AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab." Dermatitis®, 34(1), pp. 58–59FiguresReferencesRelatedDetails Volume 34Issue 1Feb 2023 Information© 2022 American Contact Dermatitis Society. All Rights Reserved.To cite this article:Ling Yu, Jianbo Wang, Lu Bian, Zhenlu Li, Ming Li, Jianguo Li, and Shoumin Zhang.Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab.Dermatitis®.Feb 2023.58-59.http://doi.org/10.1089/DERM.0000000000000954Published in Volume: 34 Issue 1: January 11, 2023PDF download

目的 分析中国银屑病的发病年龄特点,并比较不同发病年龄患者的临床特征和对生活质量的影响.方法 本研究依托银屑病规范化诊疗中心临床大数据采集平台,获取患者的临床资料信息,内容包括性别、年龄、发病年龄、身高、体重、家族史、既往史、疾病类型、严重程度、皮损分布、合并症、银屑病皮损面积和严重程度指数(PASI)、患病体表面积(BSA)及皮肤病生活质量指数(DLQI)等,将银屑病患者的临床特征和DLQI按照发病年龄进行分组分析.结果 共纳入6 134例银屑病患者,银屑病的发病高峰年龄为18～34岁,其中成人银屑病患者5 816例.发病年龄＜18岁的患者更容易累及生殖器部位(P=0.010),而发病年龄＞35岁的患者累及掌跖部位的比例更高(P＜0.001),发病年龄＞18岁的患者合并银屑病性关节炎的比例显著高于发病年龄＜18岁的患者(P=0.038),发病年龄＞35岁的患者合并高血压、糖尿病、心血管疾病的比例显著高于发病年龄＜18岁和发病年龄18～34岁的患者(P＜0.001).发病年龄＜18岁组和发病年龄18～34岁组对生活质量的影响分别是发病年龄＞35岁组的1.29倍和1.28倍(P＜0.05),对女性患者生活质量的影响是男性患者的1.26倍(P=0.005),中度和重度银屑病患者对生活质量的影响分别是轻度银屑病患者的2.49倍(P＜0.001)和5.43倍(P＜0.001),伴关节损害的银屑病患者对生活质量的影响是不伴关节损害患者的1.69倍(P=0.01).结论 不同发病年龄的银屑病患者具有不同的临床特征和生活质量.发病年龄越早可能更容易对患者的生活质量产生影响,而发病年龄越晚的患者可能更容易出现更多的合并症.